Zogenix Files For IPO

San Diego-based Zogenix said late last Thursday in a filing with the SEC that it is looking to raise up to $86.25M in an IPO on the Nasdaq Global Market. The firm said it has applied to list as "ZGNX." The IPO is being underwritten by Banc of America Securities, Leerink Swann, Thomas Weisel Partners, and Susquehanna Financial Group. Zogenix develops pharmaceuticals for the treatment of pain and central nervous system disorders; the firm's lead product is an treatment for actue migraines. Zogenix is backed by Domain Associates, Clarus Lifesciences, Scale Venture Partners, Thomas McNerney & Partners, Abingworth Bioventures, and others.